nach oben

Supportive Care in Cancer

Erschienen in:

01.08.2023 | Research

A qualitative research exploring the experiences of patients receiving immune checkpoint inhibitors for advanced lung cancer

verfasst von: Yunxia Hou, Yingge Hou, Jing Li, Lijuan Yu, Ling Yan

Erschienen in: Supportive Care in Cancer | Ausgabe 8/2023

Einloggen, um Zugang zu erhalten

Abstract

Purposes

In patients with advanced lung cancer, immune checkpoint inhibitors (ICIs) dramatically extended survival. We aimed to investigate the experiences of patients with advanced lung cancer who are receiving ICIs, with a focus on perceptions and sentiments on ICIs, to inform future research and clinical care.

Methods

Patients were recruited from January to July 2022 at Tianjin Medical University Hospital Cancer Institute & Hospital. The method of purposive sampling was used. Patients with stage IV lung cancer who were taking ICIs as a single therapy were recruited. Data were gathered using semi-structured and face-to-face interview. An inductive approach to analysis was used.

Results

Of the 42 eligible patients, 27 were invited, 20 agreed to participate, and ultimately 17 patients completed the interview. A total of 5 themes were extracted: suffered from adverse effects but generally tolerable; focus on survival, hope, and expectation; uncertainty about durability of response and the future; poor knowledge and attitude of ICIs; and financial stress and guilt over family.

Conclusion

These findings make an important contribution to healthcare professionals’ understanding of what it is like to be a patient with advanced lung cancer who is receiving ICIs. In general, the experience of immunotherapy is different from that of chemotherapy; financial and family pressures and uncertainty issues are likely to be heavier in this population. Oncology specialist nurses should provide tailored education to improve the patient’s knowledge of immunotherapy, especially to improve risk awareness of immune-related adverse events and objective prognosis expectations.

Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu XQ, He J (2016) Cancer statistics in China, 2015. CA Cancer J Clin 66:115–132. https://doi.org/10.3322/caac.21338CrossRefPubMed

Xia C, Dong X, Li H, Cao M, Sun D, He S, Yang F, Yan X, Zhang S, Li N, Chen W (2022) Cancer statistics in China and United States, 2022: profiles, trends, and determinants. Chin Med J 135:584–590. https://doi.org/10.1097/cm9.0000000000002108CrossRefPubMedPubMedCentral

Reck M, Rabe KF (2017) Precision diagnosis and treatment for advanced non-small-cell lung cancer. N Engl J Med 377:849–861. https://doi.org/10.1056/NEJMra1703413CrossRefPubMed

Siegel R, Ma J, Zou Z, Jemal A (2014) Cancer statistics, 2014. CA Cancer J Clin 64:9–29. https://doi.org/10.3322/caac.21208CrossRefPubMed

Nosaki K, Saka H, Hosomi Y, Baas P, de Castro G Jr, Reck M, Wu YL, Brahmer JR, Felip E, Sawada T, Noguchi K, Han SR, Piperdi B, Kush DA, Lopes G (2019) Safety and efficacy of pembrolizumab monotherapy in elderly patients with PD-L1-positive advanced non-small-cell lung cancer: Pooled analysis from the KEYNOTE-010, KEYNOTE-024, and KEYNOTE-042 studies. Lung Cancer 135:188–195. https://doi.org/10.1016/j.lungcan.2019.07.004CrossRefPubMed

Reck M, Rodríguez-Abreu D, Robinson AG, Hui R, Csőszi T, Fülöp A, Gottfried M, Peled N, Tafreshi A, Cuffe S, O’Brien M, Rao S, Hotta K, Leal TA, Riess JW, Jensen E, Zhao B, Pietanza MC, Brahmer JR (2021) Five-year outcomes with pembrolizumab versus chemotherapy for metastatic non-small-cell lung cancer with PD-L1 tumor proportion score ≥ 50. J Clin Oncol 39:2339–2349. https://doi.org/10.1200/jco.21.00174CrossRefPubMedPubMedCentral

Rittmeyer A, Barlesi F, Waterkamp D, Park K, Ciardiello F, von Pawel J, Gadgeel SM, Hida T, Kowalski DM, Dols MC, Cortinovis DL, Leach J, Polikoff J, Barrios C, Kabbinavar F, Frontera OA, De Marinis F, Turna H, Lee JS et al (2017) Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet 389:255–265. https://doi.org/10.1016/s0140-6736(16)32517-xCrossRefPubMed

Postow MA, Sidlow R, Hellmann MD (2018) Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med 378:158–168. https://doi.org/10.1056/NEJMra1703481CrossRefPubMed

Ala-Leppilampi K, Baker NA, McKillop C, Butler MO, Siu LL, Spreafico A, Abdul Razak AR, Joshua AM, Hogg D, Bedard PL, Leighl N, Oza AM, Parsons JA, Hansen AR (2020) Cancer patients’ experiences with immune checkpoint modulators: a qualitative study. Cancer Med 9:3015–3022. https://doi.org/10.1002/cam4.2940CrossRefPubMedPubMedCentral

10.

Jamieson L, Forster MD, Zaki K, Mithra S, Alli H, O’Connor A, Patel A, Wong ICK, Chambers P (2020) Immunotherapy and associated immune-related adverse events at a large UK centre: a mixed methods study. BMC Cancer 20:743. https://doi.org/10.1186/s12885-020-07215-3CrossRefPubMedPubMedCentral

11.

Park R, Shaw JW, Korn A, McAuliffe J (2020) The value of immunotherapy for survivors of stage IV non-small cell lung cancer: patient perspectives on quality of life. J Cancer Surviv 14:363–376. https://doi.org/10.1007/s11764-020-00853-3CrossRefPubMedPubMedCentral

12.

Rassy E, Mezquita L, Remon J, Besse B (2019) Non-small-cell lung cancer: what are the benefits and challenges of treating it with immune checkpoint inhibitors? Immunotherapy 11:1149–1160. https://doi.org/10.2217/imt-2019-0071CrossRefPubMed

13.

Nadal E, Massuti B, Dómine M, García-Campelo R, Cobo M, Felip E (2019) Immunotherapy with checkpoint inhibitors in non-small cell lung cancer: insights from long-term survivors. Cancer Immunol Immunother 68:341–352. https://doi.org/10.1007/s00262-019-02310-2CrossRefPubMed

14.

Horn L, Spigel DR, Vokes EE, Holgado E, Ready N, Steins M, Poddubskaya E, Borghaei H, Felip E, Paz-Ares L, Pluzanski A, Reckamp KL, Burgio MA, Kohlhäeufl M, Waterhouse D, Barlesi F, Antonia S, Arrieta O, Fayette J et al (2017) Nivolumab versus docetaxel in previously treated patients with advanced non-small-cell lung cancer: two-year outcomes from two randomized, open-label, phase III trials (CheckMate 017 and CheckMate 057). J Clin Oncol 35:3924–3933. https://doi.org/10.1200/jco.2017.74.3062CrossRefPubMedPubMedCentral

15.

Herbst RS, Garon EB, Kim DW, Cho BC, Perez-Gracia JL, Han JY, Arvis CD, Majem M, Forster MD, Monnet I, Novello S, Szalai Z, Gubens MA, Su WC, Ceresoli GL, Samkari A, Jensen EH, Lubiniecki GM, Baas P (2020) Long-term outcomes and retreatment among patients with previously treated, programmed death-ligand 1–positive, advanced non–small-cell lung cancer in the KEYNOTE-010 study. J Clin Oncol 38:1580–1590. https://doi.org/10.1200/jco.19.02446CrossRefPubMed

16.

Hui R, Özgüroğlu M, Villegas A, Daniel D, Vicente D, Murakami S, Yokoi T, Chiappori A, Lee KH, de Wit M, Cho BC, Gray JE, Rydén A, Viviers L, Poole L, Zhang Y, Dennis PA, Antonia SJ (2019) Patient-reported outcomes with durvalumab after chemoradiotherapy in stage III, unresectable non-small-cell lung cancer (PACIFIC): a randomised, controlled, phase 3 study. Lancet Oncol 20:1670–1680. https://doi.org/10.1016/s1470-2045(19)30519-4CrossRefPubMed

17.

Lu S, Yu Y, Yang Y (2019) Retrospect and prospect for lung cancer in China: clinical advances of immune checkpoint inhibitors. Oncologist 24:S21–s30. https://doi.org/10.1634/theoncologist.2019-IO-S1-s02CrossRefPubMedPubMedCentral

18.

Thompson C (1999) Qualitative research into nurse decision making: factors for consideration in theoretical sampling. Qual Health Res 9:815–828. https://doi.org/10.1177/104973239900900609CrossRefPubMed

19.

Patton MQ (1999) Enhancing the quality and credibility of qualitative analysis. Health Serv Res 34:1189–1208PubMedPubMedCentral

20.

Luciani M, Jack SM, Campbell K, Orr E, Durepos P, Li L, Strachan P, Di Mauro S (2019) An introduction to qualitative health research. Prof Inferm 72:60–68PubMed

21.

Thompson Burdine J, Thorne S, Sandhu G (2021) Interpretive description: a flexible qualitative methodology for medical education research. Med Educ 55:336–343. https://doi.org/10.1111/medu.14380CrossRefPubMed

22.

Thorne S (2011) Toward methodological emancipation in applied health research. Qual Health Res 21:443–453. https://doi.org/10.1177/1049732310392595CrossRefPubMed

23.

Ihrig A, Richter J, Grüllich C, Apostolidis L, Horak P, Villalobos M, Grapp M, Friederich HC, Maatouk I (2020) Patient expectations are better for immunotherapy than traditional chemotherapy for cancer. J Cancer Res Clin Oncol 146:3189–3198. https://doi.org/10.1007/s00432-020-03336-1CrossRefPubMedPubMedCentral

24.

Nishijima TF, Shachar SS, Nyrop KA, Muss HB (2017) Safety and tolerability of PD-1/PD-L1 inhibitors compared with chemotherapy in patients with advanced cancer: a meta-analysis. Oncologist 22:470–479. https://doi.org/10.1634/theoncologist.2016-0419CrossRefPubMedPubMedCentral

25.

Thong MSY, van Noorden CJF, Steindorf K, Arndt V (2020) Cancer-related fatigue: causes and current treatment options. Curr Treat Options Oncol 21:17. https://doi.org/10.1007/s11864-020-0707-5CrossRefPubMedPubMedCentral

26.

Magee DE, Hird AE, Klaassen Z, Sridhar SS, Nam RK, Wallis CJD, Kulkarni GS (2020) Adverse event profile for immunotherapy agents compared with chemotherapy in solid organ tumors: a systematic review and meta-analysis of randomized clinical trials. Ann Oncol : Offic J Europe Soc Med Oncol 31:50–60. https://doi.org/10.1016/j.annonc.2019.10.008CrossRef

27.

Marcus S (2020) Immunotherapy. JAMA Otolaryngology. Head Neck Surg 146:988. https://doi.org/10.1001/jamaoto.2020.1798CrossRef

28.

Chang CY, Park H, Malone DC, Wang CY, Wilson DL, Yeh YM, Van Boemmel-Wegmann S, Lo-Ciganic WH (2020) Immune checkpoint inhibitors and immune-related adverse events in patients with advanced melanoma: a systematic review and network meta-analysis. JAMA network open 3:e201611. https://doi.org/10.1001/jamanetworkopen.2020.1611

29.

Wong A, Billett A, Milne D (2019) Balancing the hype with reality: what do patients with advanced melanoma consider when making the decision to have immunotherapy? Oncologist 24:e1190–e1196. https://doi.org/10.1634/theoncologist.2018-0820CrossRefPubMedPubMedCentral

30.

Shuk E, Shoushtari AN, Luke J, Postow MA, Callahan M, Harding JJ, Roth KG, Flavin M, Granobles A, Christian J, Gold G, Schoenhammer M, Gordon M, Cimaglia N, Dyson R, Goodman-Davis N, Colgan MN, Jefferson IS, Munhoz R et al (2017) Patient perspectives on ipilimumab across the melanoma treatment trajectory. Support Care Cancer 25:2155–2167. https://doi.org/10.1007/s00520-017-3621-zCrossRefPubMedPubMedCentral

31.

Petrillo LA, Zhou AZ, Sullivan R, Volandes A, Greer JA, Temel JS, El-Jawahri A (2021) Knowledge about risks, benefits, and curative potential of immunotherapy among patients with advanced cancer. Oncologist 26:e2090–e2093. https://doi.org/10.1002/onco.13945CrossRefPubMedPubMedCentral

32.

Friedman CF, Proverbs-Singh TA, Postow MA (2016) Treatment of the immune-related adverse effects of immune checkpoint inhibitors: a review. JAMA Oncol 2:1346–1353. https://doi.org/10.1001/jamaoncol.2016.1051CrossRefPubMed

33.

Vaddepally R, Doddamani R, Sodavarapu S, Madam NR, Katkar R, Kutadi AP, Mathew N, Garje R, Chandra AB (2022) Review of immune-related adverse events (irAEs) in non-small-cell lung cancer (NSCLC)-their incidence, management, multiorgan irAEs, and rechallenge. Biomedicines 10. https://doi.org/10.3390/biomedicines10040790

Titel: A qualitative research exploring the experiences of patients receiving immune checkpoint inhibitors for advanced lung cancer
verfasst von: Yunxia Hou
Yingge Hou
Jing Li
Lijuan Yu
Ling Yan
Publikationsdatum: 01.08.2023
Verlag: Springer Berlin Heidelberg
Erschienen in: Supportive Care in Cancer / Ausgabe 8/2023
Print ISSN: 0941-4355
Elektronische ISSN: 1433-7339
DOI: https://doi.org/10.1007/s00520-023-07965-3

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

A qualitative research exploring the experiences of patients receiving immune checkpoint inhibitors for advanced lung cancer

Abstract

Purposes

Methods

Results

Conclusion

Neu im Fachgebiet Onkologie

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

15% bedauern gewählte Blasenkrebs-Therapie

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

Costims – das nächste heiße Ding in der Krebstherapie?

Update Onkologie

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Purposes

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 8/2023

Living with metastatic breast cancer (LIMBER): experiences, quality of life, gaps in information, care and support of patients in the UK

Clinical features and outcomes of patients admitted to the ICU for Cyclophosphamide-associated cardiac toxicity: a retrospective cohort

A cross-sectional study on Chinese oncology nurses’ knowledge of bone health among cancer patients

Do cancer centres and palliative care wards routinely measure patients’ quality of life? An international cross-sectional survey study

Correction to: Vertebral artery stenosis predicts cerebrovascular diseases following radiotherapy for nasopharyngeal carcinoma

Correspondence: Significance of localized expression of full-length growth differentiation factor-15 in cachexia of advanced non-small cell lung cancer

Neu im Fachgebiet Onkologie

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

15% bedauern gewählte Blasenkrebs-Therapie

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

Costims – das nächste heiße Ding in der Krebstherapie?

Update Onkologie